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Lactic acid bacteria (LAB) are Gram-positive, nonpathogenic microorganisms that are gaining much interest as antigen producers
for development of live vaccine vectors. Heterologous proteins of different origin have been successfully expressed in various
LAB species, including Lactococcus lactis. Recombinant L. lactis strains have been shown to induce specific local and systemic
immune responses against various antigens. Our study aimed at constructing a L. lactis strain expressing haemagglutinin of a
Polish avian H5H1 influenza isolate and examining its effect on animals. Expression of the cloned H5 gene was achieved using the
nisin-controlled gene expression system. Detection of the intracellular H5 antigen produced in L. lactis was performed byWestern
blot analysis and confirmed usingmass spectrometry.The potential of L. lactis recombinant cells to induce an immune response was
examined by setting up preliminary immunization trials on chickens andmice. Obtained sera were tested for specific antibodies by
ELISA assays. The results of these studies are a promising step toward developing a vaccine against the bird flu using Lactococcus
lactis cells as bioreactors for efficient antigen production and delivery to the mucosal surface.
1. Introduction
Lactococcus lactis are noninvasive, nonpathogenic bacteria,
used widely inmanufacturing ofmilk fermentation products.
Lack of lipopolysaccharide (LPS) and enterotoxins and the
generally acknowledged food-grade status make L. lactis cells
a useful tool for bioengineering processes. In the last several
decades lactococci have been exploited as hosts for expression
of heterologous antigen proteins, including those of thera-
peutic and prophylactic activity [1, 2]. Among them, a L.
lactis-based interleukin-10 (IL-10) formulation has been sub-
jected to phase II clinical trials of inflammatory bowel disease
(IBD) therapy [3]. Latest studies focus on employing these
bacteria as live vaccine delivery systems to mucosal surfaces
by oral or intranasal routes [4–6]. Mucosal epithelial cells
constitute an entry for infectious agents, including influenza
viruses. It is expected that vaccines directed to mucosal sur-
faces will induce immune responses, providing both mucosal
and systemic protection. Moreover, advantages of mucos-
ally administered versus traditional (parenteral) vaccinations
include low cost and easy and painless antigen dosage, which
is especially beneficial for large-scale immunizations of farm
animals or human populations. Mucosally administered vac-
cines based on recombinant L. lactis cells producing various
antigens were shown to evoke specific immune responses
of humoral and cell-mediated type [7–10]. At the same
time, it has been demonstrated that certain L. lactis strains
(e.g., NZ9000) exhibit innate adjuvant properties, which can
enhance specific immune response to administered antigens
[11–13]. This feature is advantageous especially that mucos-
ally applied vaccine preparations alone usually present low
immunogenicity [14, 15]. Additionally, the general inability of
L. lactis as noncommensal, noncolonizing bacteria to grow or
replicate in vivo limits its potential to evoke oral tolerance [8,
16]. Furthermore, L. lactis-produced antigens are presented to
the immune system in particulate form, which is postulated
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to evoke stronger mucosal response than soluble proteins
[17, 18].The great potential of L. lactis cells has been exploited
by ActoGeniX, which is one of the first companies to
develop recombinant biologically contained strains (termed
ActoBiotics) for clinical purposes [3].
In our study, we cloned the codon-optimized gene
encoding haemagglutinin of the H5N1 influenza virus and
expressed it intracellularly using the nisin-controlled gene
expression (NICE) system in L. lactis NZ9000 strain. The
strain carries two signal transduction genes, nisK and nisR,
integrated into the chromosome, which regulate the nisin-
induced promoter PnisA present in the vector. The system
allows efficient but controlled expression of recombinant
genes in L. lactis cells, including toxic proteins, on lab and
industrial scales [19, 20].
Our study was based on the HA gene of the H5N1
A/swan/Poland/305-135V08/2006 virus isolated from a wild
swan during a highly pathogenic avian influenza outbreak in
2006 in Poland. Due to the realistic threat of an epidemic
spread (for the first time in this country), development of an
efficient and safe vaccine for protection of local farm poultry
flocks based on the H5 antigen from this specific isolate was
greatly sought. Haemagglutinin (HA) is the most abundant
and immunogenic protein on the surface of the influenza
virus which plays role in the initial steps of host infection
[21]. It was shown to induce specific antibodies and is by far
themost widely used antigen in designing human and animal
vaccines against flu [22–24]. Also in chickens, the HA protein
of the avian influenza virus (AIV) was shown to elicit specific
immune response [25]. Although AIV develops in birds as
natural hosts, interspecies infections, including human, have
also been reported. Based on the statements of the World
Human Organization (WHO), more than 50% of confirmed
human cases of H5N1 led to death in years 2003–2016 [26].
Transmission of AIV to humans has been linked to domestic
birds, such as chickens [23].Therefore, the risk of interspecies
barrier break and effective AIV infection in humans and its
further spread in the human population is apparent. For that
reason, developing a strategy of fast and cheap production of
protective anti-H5N1 vaccine for wide-scale immunization of
farm birds is strongly desirable.
Our results, based on preliminary animal trials, show that
it is possible to elicit an immune response by oral delivery
of live H5-producing L. lactis cells. Specific antibody titers
were examined in ELISA assays to assess the efficacy of the
vaccination strategy. Variations in response between exam-
ined animal species (chickens and mice) were determined.
The work provides data that sets a basis for developing an
effective vaccine formulation for birds using recombinant L.
lactis against H5N1 infection.
2. Materials and Methods
2.1. Bacterial Strain, Vector, and Growth Conditions. Lacto-
coccus lactis NZ9000 strain and pNZ8150 (MoBiTec) were
used, respectively, as the antigen expression host and plas-
mid vector. Bacterial cells were cultured at 30∘C in M17
(Oxoid) broth [27] containing 0.5% glucose (GM17) without
shaking or on GM17 plates with 1.5% agar. For selection
of pNZ8150-carrying strain and its recombinant variants,
chloramphenicol (Cm) was added to the growth medium at
a concentration of 10 𝜇gml−1. Prior to their use, bacterial
cells for immunization trials were suspended in PBS, pH 7.4,
supplemented with 20% (v/v) trehalose to maintain viability
during storage and postthaw handling.
2.2. SequenceModification and Cloning of H5 Gene in L. lactis.
Gene encoding the H5 nucleocapsid protein of the avian
influenza virus H5N1 A/swan/Poland/305-135V08/2006
strain from AIV EpiFlu Database [http://platform.gisaid.org]
(accession number: EP1156789) was commercially
synthesized by GeneArt. For stability, DNA fragment
corresponding to the protein’s proteolytic cleavage site
(ΔRRRKKR aa) was deleted from the original nucleotide
sequence. For efficient translation and mRNA stability in L.
lactis cells, codon optimization was performed by modifying
the H5 nucleotide sequence using the GeneOptimizer
software. The codon-optimized H5 nucleotide sequence was
amplified by PCR reaction using FHASnisScaI/RHASSacI (5󸀠
ATGGAAAAAATTGTTCTT 3󸀠/5󸀠 GCCGAGCTCGTTA-
AATACAAATACG 3󸀠) primers and Pfu DNA Polymerase
(Thermo Fisher Scientific) generating blunt ends. The
5󸀠 end of the reverse primer was adapted to contain
the SacI restriction site (in bold). Next, the generated
PCR fragment was subjected to SacI digestion (Thermo
Fisher Scientific) and then blunt-sticky end ligation with
pNZ8150 cut previously with SacI/ScaI enzymes. In effect, a
translational fusionwith thenisApromoterwas obtained.The
resulting recombinant plasmid was termed pNZ8150:H5 and
introduced into L. lactis NZ9000 cells via electroporation.
2.3. DNA Manipulations, Transformation of Bacterial Cells,
and Identification of Recombinant Clones. DNA molecular
cloning and restriction enzyme analysis were performed
according to general procedures [28]. L. lactisNZ9000 strain
cells were made electrocompetent for transformation as
already described [29, 30]. Transformants were selected on
GM17 plates supplemented with Cm and further analyzed by
“colony PCR” using primers nisF/nisR (5󸀠 AACTACAAA-
ATAAATTATAAGGAGGCACTC3󸀠/5󸀠 GTTTCAAGC-
CTTGGTTTTCTAATTTTGG3󸀠). Plasmid DNA was iso-
lated using PureYield PlasmidMiniprep system (Promega).
Prior to the isolation step, the cell suspension was incubated
in TES buffer (25mM Tris-HCl, pH 8, 10mM EDTA, and 1%
saccharose) with lysozyme (8mgml−1) for 30min at 37∘C to
disrupt the peptidoglycan layer and increase the efficiency of
plasmidDNA recuperation.Obtained recombinant construct
was subjected to DNA restriction analysis. Finally, nucleotide
sequence of the cloned DNA fragment was confirmed by
sequencing (GS FLX Titanium 454, Roche). The resulting L.
lactis NZ9000 strain carrying the pNZ8150:H5 recombinant
vector was termed NZ-H5.
2.4. Immunodetection. Intracellular production of H5 in
recombinant bacteria was examined by growing NZ-H5 cells
at 30∘C on GM17 (Oxoid) medium supplemented with Cm
(10 𝜇gml−1). At log-phase (OD
600
0.4), nisin (5 ngml−1)
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was added to induce gene expression. Culture samples
were harvested 1, 2, and 3 h after induction. Subsequently,
crude extracts were obtained by disrupting the cells 5x
for 45 sec with 1.5min intervals on ice using the Mini-
BeadBeater (BioSpec Products) and glass beads (106 𝜇m
diameter; Sigma). To inhibit potential degradation, each
sample was combined with a protease inhibitor according to
the manufacturer’s instruction (Roche). Cellular debris and
glass beads were removed by centrifugation for 10min at
8,000 rpm and 4∘C. Protein extracts were combined with an
equal volume of 2x loading buffer (125mMTris-HCl, pH 6.8,
4% SDS, 10% 𝛽-mercaptoethanol, 20% glycerol, and 0.01%
bromophenol blue), heated for 5min at 95∘C. Next, protein
samples were separated on a 12% polyacrylamide gel by SDS-
PAGE (120V, 500mA) and subsequently transferred onto
nitrocellulose Hybond-C Extra membrane (Amersham).The
membrane was blocked overnight at 4∘C with TBS-T buffer
(20mM Tris, pH 8, 150mM NaCl, and 0.1% Tween 20),
containing 3% skimmed milk. Immunoblotting was carried
out using commercial monoclonal anti-H5mouse antibodies
(Abcam) at 1 : 500 dilution, followed by detection with sec-
ondary anti-IgG mouse antibodies conjugated with alkaline
phosphatase (Sigma) at dilution 1 : 15,000. Immunoblots were
resolved using NBT/BCIP Stock Solution (Roche) in ALT
(1ml 1M Tris, pH 8.0, 1ml 1M NaCl, and 0.5ml 1M MgCl
2
)
buffer. 293 cell culture-purified Qinghai-HA(H5N1)(A/Bar-
headedGoose/Qinghai/12/05) protein (ImmuneTechnology)
was used as a positive control. Data was normalized using
protein samples from cells carrying the empty vector (NZ
[pNZ8150]).
2.5. Mass Spectrometry and Protein Identification. Proteomic
analyses presented in this work were performed in the
Laboratory of Mass Spectrometry at IBB PAS. Briefly, gel-
excised protein samples were reduced with 100mMDTT (30
minutes at 56∘C) and alkylated with 0.5M iodoacetamide (45
minutes in a darkroom at RT), followed by trypsin (10 ng 𝜇l−1,
Promega) overnight digestion at 37∘C. Peptide mixtures were
concentrated, desalted on a RP-C18 precolumn (Waters),
and separated on a nano-Ultra Performance Liquid Chro-
matography (UPLC) RP-C18 column (Waters, BEH130 C18
column, 75 𝜇m i.d., 250mm long), using a 160min gradient
from 5 to 30% of acetonitrile. Measurements were performed
with the Orbitrap Velos spectrophotometer (Thermo Fisher
Scientific), working in the regime of data-dependent MS
to MS/MS switch with HCD type peptide fragmentation.
Identification of proteins was performed using the Mascot
search engine (Matrix Science) with the probability-based
algorithm.Datawere searchedwith automatic decoy database
and filtered to obtain a false discovery rate below 1%.
2.6. Animal Immunization and Sera Collection. Leghorn
White laying type chickens were housed in cages in an experi-
mental poultry house under standard commercial conditions.
Female BALB/c mice (supplied by Mossakowski Medical
Research Centre of the Polish Academy of Sciences, Warsaw,
Poland) were kept in a temperature-controlled environment
at 24∘Cwith 12 h day-night cycles and received food andwater
ad libitum.
Vaccination was performed using a prime-boost strategy.
One-day-old chickens or eight-week-old mice were immu-
nized orally using a gauge syringe with 109 CFU of NZ-H5
cells or respective amount of cell lysates (L-H5). Cells carry-
ing the empty vector (NZ[pNZ8150]) and crude cell extract
(L-pNZ8150) served as respective negative controls. Doses
were administered on days 1–3 and then again as two boosters
at two-week intervals (on days 7–9 and 21–23 for chickens
or days 14–16 and 28–30 for mice). Blood samples from the
wing veins (chickens) or orbital sinus (mice) were collected
on day 20 and day 38 (day of termination) for chickens
and day 9, 17, 25, and 41 (day of termination) for mice. To
obtain serum, whole blood samples were left to coagulate at
room temperature for approximately 15 to 30 minutes. Then,
samples were centrifuged twice at 4∘C for approximately
10min at 10,000𝑔 and stored at −80∘C. Mice feces samples
(0.1 g) for IgA detection were collected on days 0, 9, 17, 25,
and 41 and combined with 1ml of PBS buffer containing
protease inhibitor at a given concentration (Roche). Samples
were vigorously vortexed and then centrifuged at 10,000𝑔
for 10min at 4∘C. The supernatant was collected and kept at
−80∘C until further use.
2.7. Enzyme-Linked Immunosorbent Assay. Sera from immu-
nized animals were subjected to ELISA assays for detection
of specific IgY (chickens) and IgG and IgA (mice). In
short, MaxiSorp plates (Nunc) were coated with recombinant
H5 protein of A/Bar-headed Goose/Qinghai/12/05 (H5N1)
strain of influenza A virus (3 𝜇gml−1 in PBS, overnight, 2–
8∘C) (Immune Technology). The next day, serum samples
were diluted 1 : 25 in 2% BSA-PBS, applied onto plates, and
incubated overnight at 2–8∘C. Proper controls and blanks
(sample diluent) were included. Secondary labeling and
detection were done with Sigma-Aldrich reagents unless
specified otherwise. Antibody classes were detected with goat
(HRP)-labeled antibodies against chickens IgY at 1 : 2500
dilution or against mouse IgG and IgA at 1 : 500 dilution
(Thermo Fisher Scientific) (1 h, 37∘C). Tetramethylbenzidine
(TMB) was used as a substrate. Reactions were performed at
room temperature for 30min and then stopped by adding
0.5M sulfuric acid. Absorbance was read at 450 nm with
subtraction of themeanOD readings of blanks. Samples were
determined to be positive for anti-H5 antibodies when OD
readings were 2 SD above the mean OD of samples from
sham-immunized animals (cut-off value).
3. Results
3.1. Recombinant H5 Expression in L. lactis NZ9000. The
codon-optimized H5 gene was cloned under the nisA pro-
moter in pNZ8150 vector and introduced to L. lactisNZ9000
generating the recombinant NZ-H5 strain. Log-phase cul-
tures ofNZ-H5 and the negative control (NZ[pNZ8150])were
induced for intracellular antigen production by addition of
nisin and further growth for 1, 2, or 3 hrs. After disruption of
collected cultures, crude cell extracts were subjected to SDS-
PAGE followed by immunoenzyme reaction using specific
H5 antibodies. Antigen-specific signals corresponding to the
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Figure 1: Immunoblot detection of H5 production under nisA
promoter in L. lactis NZ9000 cells at different induction times.
M: marker, Precision Plus Protein Dual Color Standards (Bio-
Rad). Protein extracts: lane 1, NZ[pNZ8150] (negative control);
lanes 2, 3, and 4, NZ-H5 after nisin (5 ngml−1) induction
for 1, 2, or 3 hrs, respectively. Qinghai-HA(H5N1)(A/Bar-headed
Goose/Qinghai/12/05) protein (Immune Technology) was used as
a positive control (C+).The migration level of bands corresponding
to detected H5 recombinant protein (63 kDa) is marked by a black
arrow.
Figure 2: Peptides detected by mass spectrometry from H5
immunoreactive gel-excised band.
full-length protein (63 kDa) were identified in all NZ-H5
samples collected at different times after induction (Figure 1,
lanes 2, 3, and 4) and were absent for the NZ[pNZ8150]
control (Figure 1, lane 1). Obtained results confirmed intra-
cellular production of H5 in L. lactis cells under the tested
nisin concentration and times of induction.
3.2. H5 Identification by Mass Spectrometry. To confirm that
the observed signal corresponds to theH5 protein, the 63 kDa
immunoreactive band was excised from the SDS-PAGE
gel and subjected to mass spectrometry analysis. Detected
peptides were identified as fragments of the H5 protein.
Obtained results were consistent with Western blot analysis,
confirming antigen production in L. lactis cells (Figure 2).
3.3. Study of H5-Specific Immune Responses in Chickens
and Mice. To assess the immunoefficiency of recombinant
H5 produced in L. lactis, preliminary vaccination trials
were performed on chickens. Birds were fed with NZ-H5
cells, L-H5 lysates, or respective controls (NZ[pNZ8150]
or L-pNZ8150) using an established prime-boost scheme.
Antigen-specific IgY titers were measured approximately 3
and 5 weeks after prime immunization (Figures 3(a) and
3(b)). NZ-H5 cells elicited immunoresponse in three out of
ten chickens tested. In one bird, IgY titer was higher than
in others and further increased after the second boosting
(Figure 3(a)). Compared to theNZ-H5 group, chickens vacci-
natedwith L-H5 showed a significantly higher level of specific
IgY antibodies (Figure 3(b)). In this case, half of the birds
responded three weeks after the initial immunization. This
effect was maintained after the second booster with a further
increase in IgY titer.
To examine whether more eminent immune responses
can be obtained with recombinant H5-expressing L. lactis
cells, a well-adapted laboratory mouse model was used, and
necessary negative controls were applied (NZ[pNZ8150] or L-
pNZ8150). For animals vaccinatedwithNZ-H5 cells, anti-HA
IgG and IgA titers were just above or below the threshold level
(Suppl. Figure 1 in Supplementary Material available online
at https://doi.org/10.1155/2017/6747482). Alternatively, higher
levels of specific antibodieswere noted after administration of
L-H5 lysates (Suppl. Figure 2). Here, several mice responded
positively giving a rise in IgG isotype. For one animal, the
most profound IgG peak was noted 9 days after the first
booster (day 25) (Suppl. Figure 2A). Two mice responded
by a raise of both IgG and IgA. Highest IgA titers were
observed 11 days after the second booster (day 41) (Suppl.
Figure 2B). Nonetheless, these results conclude that the
applied immunization scheme could elicit only a very weak
immunoresponse in mice under the tested conditions.
4. Discussion
The use of L. lactis cells as live delivery vectors has gained
much interest over the last years as an alternative method
of vaccination. Such approach is especially attractive with
regard to prevention of massive disease spreads in animals,
including avian influenza outbreaks. It excludes the necessity
of traditional vaccination based on manual injection, which
in case of numerous bird flocks can be quite laborious.
Administration of antigens produced in L. lactis to gut
mucosa via the oral route is reported to be effective in
triggering both local and systemic immune responses [4,
31]. It is postulated that mucosally administrated vaccines
via oral or nasal routes demand adjuvants to elicit specific
protective responses. In this aspect of vaccine development,
L. lactis cells seem to be an attractive antigen producer as
they were shown to have intrinsic adjuvant properties [12].
Specifically for the lactococcal NZ9000 strain, recent in vitro
studies demonstrate its potential to evoke immune response
by induction of cytokines andmaturation of dendritic cells in
bone marrow [32].
In this work, we evaluated the efficiency of expression
of haemagglutinin of the avian influenza H5N1 A/swan/
Poland/305-135V08/2006 isolate inL. lactis cells. In our previ-
ouswork,we have shown that it is possible to engineerL. lactis
cells to produce the H5 protein of the avian influenza virus
H5N1 [33]. In this study, we aimed at further improvement
of the approach. To reduce the potential protein toxicity,
expression of H5 was carried out under the nisin-inducible






































(b) Serum IgY L-H5 extracts
Figure 3: Specific serum antibody response in chickens fed with L. lactisNZ-H5 or respective cell lysates L-H5. Animals (𝑛 = 10) were given
109 CFUof bacteria (a) or respective amounts of cell lysates (b) on daysmarked by arrows. H5-specific IgY titers weremeasured in serum sam-
ples collected on days 20 and 38 at 1 : 25 dilution. Graphs show results obtained for each immunized chicken at given time point of blood sam-
pling (diamonds).Datawas normalized by adapting the cut-off (point 0 on the axis) asmeanODreadings higher by 2 SD than for control birds.
promoter (PnisA) using the NICE system [19]. Its tight
regulation allows for stable expression of proteins of various
function and origin [34–38].Western blot assays revealed the
presence of an immunospecific band of 63 kDa, irrelevant of
induction time, which corresponded to H5. The size of the
recombinant H5 (63 kDa) was slightly different from that of
the H5Qinghai reference protein, whichmigrated at the level
of the 75 kDa band of the protein marker. This size difference
is most probably related to the protein producer (L. lactis
versus eukaryotic cell line, resp.). Posttranslational modi-
fications (e.g., glycosylation and phosphorylation), known
to occur in eukaryotic cells, which are often lacking in
prokaryotic hosts (in L. lactis cells glycosylation was not
determined), may contribute to the molecular weight varia-
tions of these two H5 proteins.Therefore, mass spectrometry
analysis was conducted and has confirmed the identity of the
protein. The obtained data clearly evidence the production
of the H5 protein of the avian influenza virus H5N1 in L.
lactis cells. Immunogenicity of the recombinant antigen was
preliminarily screened using two animal models. In mice,
very low IgG and IgA antibody titers were detected in single
animals. More enhanced levels of specific anti-H5 antibodies
(IgY) were detected in chickens. The most pronounced effect
was noted for birds ingested with preparations containing
crude extracts L-H5. Variations in response between animal
species, at least in part, reflect the acknowledged diversity
of immunological systems of birds and mice (mammals)
[39]. Moreover, the receptor binding profiles of avian versus
mammalian (human) type A influenza viruses are different
[40, 41].While haemagglutinin of human viruses participates
in recognition of receptors in the respiratory tract (𝛼2-6-
galactose linked sialic acids), avian viruses bind to receptors
in intestinal epithelium cells (𝛼2-3-galactose linked sialic
acids) [42]. It is feasible that the divergence in discerning
L. lactis-produced H5 by epithelial cells of the two species
accounts for variations in the response observed during
animal immunization trials.
The objective of the study was to design a biological
L. lactis-based platform for H5 protein production and its
easy delivery to gut mucosa. Intracellular localization of the
protein was intended in order to protect the antigen during
passage through the stomach before reaching the intestine.
This approach was envisaged as advantageous especially for
large-scale immunizations of farm animals, such as chickens,
where the recombinant L. lactis could be administered in
food or drinking water. As fate of recombinant Lactococcus
cells (degree and rate of lysis) was hard to predict, animals
were also immunized with whole-cell lysate preparations (L-
H5). ELISA assays revealed differences in the levels of specific
antibody titers depending on the type of immunization
preparation. The higher number of chickens responding
in detectable IgY titers after administration of whole-cell
extracts (L-H5) suggests that in this form the antigen is more
immunogenic. It is probable that even higher overall specific
antibody titers could be obtained by designing recombinant
cells, where the H5 antigen is anchored to the cell wall. A
series of studies confirmed that cell surface-exposed antigens
in L. lactis are produced at higher levels, are more stable, and
elicit stronger immune responses after mucosal vaccination
than their cytoplasmic forms [43–46]. In L. lactis cells,
internally localized heterologous proteins are often degraded
due to activity of proteolytic proteins, which potentially can
account for a weaker answer from the immune system [47,
48]. Another crucial aspect in development of an efficient
immune response is protein folding and exposition of specific
conformational epitopes. The inability to identify the recom-
binant H5 under nondenaturing Western blot conditions
(data not shown), suggests altered protein conformation
(although other unknown cellular factors influencing this
state cannot be excluded) with respect to the control protein.
This may impact the antibody titers detected in ELISA
assays. From another point of view, low serum antibody
titers may also suggest poor exposition of the cell-enclosed
protein to gut mucosa. Despite the anticipated breakage
of L. lactis cells, it cannot be excluded that the generally
lower effect of recombinant NZ-H5 is additionally due to the
presence of trehalose in the bacterial preparations. Trehalose
is a cryoprotectant, known to stabilize biological membrane
6 BioMed Research International
bilayers [49]. The intention to use trehalose was to protect
the cells from freeze/thaw handling. The compound was also
anticipated to protect recombinant bacteria from gastric acid
before reaching the gut as noted by Bahey-El-Din [50]. Our
results suggest that trehalose may reduce cell lysis also in
further parts of the GI tract, which is reflected by higher
anti-HA specific antibody titers for lysate (L-H5) versus
recombinant cell preparations.
In the course of this study, we determined that the H5
antigen from the avian influenza virusH5N1 can be produced
in L. lactis cells. Preliminary oral animal immunizations
revealed a difference in the response levels between different
species. Our study clearly shows that it is of significant
importance to test potential vaccine formulations on target
hosts as direct extrapolation of immunization effects per-
formed on model animal species may not necessarily be
valid. Moreover, we achieved higher antibody responses with
crude cell extracts (L-H5) rather than intracellular localized
protein (NZ-H5). Under the tested immunization schemes,
fluctuations in specific serum titers were observed between
individual chickens. However, in positively responding birds,
anti-HA antibody levels increased after subsequent boosting,
indicating that a properly developed immune reaction can
be maintained during the time course of the study. Further
modifications of the immunization scheme are anticipated
to determine the most effective procedure of dosing the
recombinant bacterial preparations. Overall, production of
H5 in L. lactis cells and the observed immune response after
oral administration of recombinant bacteria are a starting
point in developing an effective preparation for immunizing
birds against avian flu.
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